Phase 2 N=76 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Tumor Response — 1; 7; 17; 34 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=58 Dose-Intense Temozolomide in Recurrent Glioblastoma
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression Free Survival — 11 percentage of evaluable participants
Phase 2 N=23 Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Maximum T Cell Response From Baseline — 10.5; 51.75; 270.625 spots per 10^4 CD8+ cells — p=0.028
Phase 2 N=104 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
Phase 2 N=500 A/H5N1/LT Dose Ranging Study
Pandemic Influenza
Primary: Assess the Proportion of Subjects in Each Dose Group Achieving Seroconversion and Seroprotection for HI Antibody Titer Through Day 28. — 35.4; 47.4; 37.6; 53.1…
Phase 2 N=600 Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
Diarrhea
Primary: Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs…
Phase 2 N=102 Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177
Phase 2 N=126 Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
Human Influenza
Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV — 52; 41; 100; 78…
Phase 2 N=41 Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 30 percentage of participants
Phase 2 N=50 Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Lung Cancer
Primary: Time to Progression — 123 days
Phase 2 N=260 Comparing Smoking Treatment Programs for Lighter Smokers - 1
Tobacco Use Disorder
Primary: Percent Treatment Sessions Attended — 77.9; 85.9; 66.8; 66.6 Percentage of attended tx. sessions — p=<0.017
Phase 2 N=120 Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine
Meningococcal Disease
Primary: Persistence of Serum Bactericidal Antibody Titers in Children (at 40 Months of Age), Twenty-eight Months After Completing Primary Vaccination. — 1.26; 2.55; 1.08; 41…
Phase 2 N=9 Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
Weight Gain
Primary: Change From Baseline to Week 24 in Body Mass Index (BMI) — 1.620; 1.800 kg/m^2
Phase 2 N=92 Prevention of Acute Kidney Injury in Cardiac Surgery Patients
Kidney Injury
Primary: Number of Participants With Acute Kidney Injury — 20; 14 participants
Phase 2 N=29 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Liposarcoma,Myxoid
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants